160 related articles for article (PubMed ID: 33205203)
21. Human papillomavirus prevalence and type distribution in urine samples from Norwegian women aged 17 and 21 years: A nationwide cross-sectional study of three non-vaccinated birth cohorts.
Molden T; Feiring B; Ambur OH; Christiansen IK; Hansen M; Laake I; Meisal R; Myrvang E; Jonassen CM; Trogstad L
Papillomavirus Res; 2016 Dec; 2():153-158. PubMed ID: 29074174
[TBL] [Abstract][Full Text] [Related]
22. Prevalence of Oral Human Papillomavirus Infection: Impact of Sex, Race/Ethnicity, and Vaccination Status.
Berenson AB; Hirth JM; Chang M
Clin Infect Dis; 2022 Apr; 74(7):1230-1236. PubMed ID: 34218280
[TBL] [Abstract][Full Text] [Related]
23. Human Papillomavirus (HPV) Prevalence in Male Adolescents 4 Years After HPV-16/18 Vaccination.
Lehtinen T; Söderlund-Strand A; Petäjä T; Eriksson T; Jokiranta S; Natunen K; Dillner J; Lehtinen M
J Infect Dis; 2017 Nov; 216(8):966-968. PubMed ID: 28968844
[TBL] [Abstract][Full Text] [Related]
24. Long-term follow-up of human papillomavirus type replacement among young pregnant Finnish females before and after a community-randomised HPV vaccination trial with moderate coverage.
Gray P; Kann H; Pimenoff VN; Adhikari I; Eriksson T; Surcel HM; Vänskä S; Dillner J; Faust H; Lehtinen M
Int J Cancer; 2020 Dec; 147(12):3511-3522. PubMed ID: 32574384
[TBL] [Abstract][Full Text] [Related]
25. Quadrivalent vaccine-targeted human papillomavirus genotypes in heterosexual men after the Australian female human papillomavirus vaccination programme: a retrospective observational study.
Chow EPF; Machalek DA; Tabrizi SN; Danielewski JA; Fehler G; Bradshaw CS; Garland SM; Chen MY; Fairley CK
Lancet Infect Dis; 2017 Jan; 17(1):68-77. PubMed ID: 27282422
[TBL] [Abstract][Full Text] [Related]
26. Gender-neutral vaccination provides improved control of human papillomavirus types 18/31/33/35 through herd immunity: Results of a community randomized trial (III).
Lehtinen M; Luostarinen T; Vänskä S; Söderlund-Strand A; Eriksson T; Natunen K; Apter D; Baussano I; Harjula K; Hokkanen M; Kuortti M; Palmroth J; Petäjä T; Pukkala E; Rekonen S; Siitari-Mattila M; Surcel HM; Tuomivaara L; Paavonen J; Nieminen P; Dillner J; Dubin G; Garnett G
Int J Cancer; 2018 Nov; 143(9):2299-2310. PubMed ID: 29845626
[TBL] [Abstract][Full Text] [Related]
27. Knowledge of HPV infection and vaccination among vaccinated and unvaccinated teenaged girls.
Sopracordevole F; Cigolot F; Mancioli F; Agarossi A; Boselli F; Ciavattini A
Int J Gynaecol Obstet; 2013 Jul; 122(1):48-51. PubMed ID: 23523333
[TBL] [Abstract][Full Text] [Related]
28. Facilitators and barriers HPV unvaccinated girls after 5 years of program implementation.
Firenze A; Marsala MG; Bonanno V; Maranto M; Ferrara C; Giovannelli L; Restivo V
Hum Vaccin Immunother; 2015; 11(1):240-4. PubMed ID: 25483543
[TBL] [Abstract][Full Text] [Related]
29. Changes in (risk) behavior and HPV knowledge among Dutch girls eligible for HPV vaccination: an observational cohort study.
Donken R; Tami A; Knol MJ; Lubbers K; van der Sande MAB; Nijman HW; Daemen T; Weijmar Schultz WCM; de Melker HE
BMC Public Health; 2018 Jul; 18(1):837. PubMed ID: 29976170
[TBL] [Abstract][Full Text] [Related]
30. Effectiveness of Human Papillomavirus Vaccination on Prevalence of Vaccine Genotypes in Young Sexually Active Women in France.
Heard I; Tondeur L; Arowas L; Demazoin M; Falguières M; Parent Du Chatelet I;
J Infect Dis; 2017 Mar; 215(5):757-763. PubMed ID: 28011911
[TBL] [Abstract][Full Text] [Related]
31. Human papillomavirus vaccination and all-cause morbidity in adolescent girls: a cohort study of absence from school due to illness.
Hviid A; Thorsen NM; Thomsen LN; Møller FT; Wiwe A; Frisch M; Valentiner-Branth P; Rytter D; Mølbak K
Int J Epidemiol; 2021 May; 50(2):518-526. PubMed ID: 33547468
[TBL] [Abstract][Full Text] [Related]
32. Human Papillomavirus prevalence and probable first effects of vaccination in 20 to 25 year-old women in Germany: a population-based cross-sectional study via home-based self-sampling.
Deleré Y; Remschmidt C; Leuschner J; Schuster M; Fesenfeld M; Schneider A; Wichmann O; Kaufmann AM
BMC Infect Dis; 2014 Feb; 14():87. PubMed ID: 24552260
[TBL] [Abstract][Full Text] [Related]
33. Prevalence of human papillomavirus in young men who have sex with men after the implementation of gender-neutral HPV vaccination: a repeated cross-sectional study.
Chow EPF; Tabrizi SN; Fairley CK; Wigan R; Machalek DA; Garland SM; Cornall AM; Atchison S; Hocking JS; Bradshaw CS; Balgovind P; Murray GL; Chen MY
Lancet Infect Dis; 2021 Oct; 21(10):1448-1457. PubMed ID: 34043963
[TBL] [Abstract][Full Text] [Related]
34. Final analysis of a study assessing genital human papillomavirus genoprevalence in young Australian women, following eight years of a national vaccination program.
Garland SM; Cornall AM; Brotherton JML; Wark JD; Malloy MJ; Tabrizi SN;
Vaccine; 2018 May; 36(23):3221-3230. PubMed ID: 29724506
[TBL] [Abstract][Full Text] [Related]
35. Impact of gender-neutral or girls-only vaccination against human papillomavirus-Results of a community-randomized clinical trial (I).
Lehtinen M; Söderlund-Strand A; Vänskä S; Luostarinen T; Eriksson T; Natunen K; Apter D; Baussano I; Harjula K; Hokkanen M; Kuortti M; Palmroth J; Petäjä T; Pukkala E; Rekonen S; Siitari-Mattila M; Surcel HM; Tuomivaara L; Paavonen J; Dillner J; Dubin G; Garnett G
Int J Cancer; 2018 Mar; 142(5):949-958. PubMed ID: 29055031
[TBL] [Abstract][Full Text] [Related]
36. Modelling the population-level impact of vaccination on the transmission of human papillomavirus type 16 in Australia.
Regan DG; Philp DJ; Hocking JS; Law MG
Sex Health; 2007 Sep; 4(3):147-63. PubMed ID: 17931528
[TBL] [Abstract][Full Text] [Related]
37. Protection to Self and to One's Sexual Partner After Human Papillomavirus Vaccination: Preliminary Analysis From the Transmission Reduction And Prevention with HPV Vaccination Study.
MacCosham A; El-Zein M; Burchell AN; Tellier PP; Coutlée F; Franco EL;
Sex Transm Dis; 2022 Jun; 49(6):414-422. PubMed ID: 35235550
[TBL] [Abstract][Full Text] [Related]
38. Quadrivalent human papillomavirus vaccine effectiveness: a Swedish national cohort study.
Leval A; Herweijer E; Ploner A; Eloranta S; Fridman Simard J; Dillner J; Young C; Netterlid E; Sparén P; Arnheim-Dahlström L
J Natl Cancer Inst; 2013 Apr; 105(7):469-74. PubMed ID: 23486550
[TBL] [Abstract][Full Text] [Related]
39. Effect of vaccination against oral HPV-16 infection in high school students in the city of Cali, Colombia.
Castillo A; Osorio JC; Fernández A; Méndez F; Alarcón L; Arturo G; Herrero R; Bravo LE
Papillomavirus Res; 2019 Jun; 7():112-117. PubMed ID: 30851448
[TBL] [Abstract][Full Text] [Related]
40. Immunogenicity and HPV infection after one, two, and three doses of quadrivalent HPV vaccine in girls in India: a multicentre prospective cohort study.
Sankaranarayanan R; Prabhu PR; Pawlita M; Gheit T; Bhatla N; Muwonge R; Nene BM; Esmy PO; Joshi S; Poli UR; Jivarajani P; Verma Y; Zomawia E; Siddiqi M; Shastri SS; Jayant K; Malvi SG; Lucas E; Michel A; Butt J; Vijayamma JM; Sankaran S; Kannan TP; Varghese R; Divate U; Thomas S; Joshi G; Willhauck-Fleckenstein M; Waterboer T; Müller M; Sehr P; Hingmire S; Kriplani A; Mishra G; Pimple S; Jadhav R; Sauvaget C; Tommasino M; Pillai MR;
Lancet Oncol; 2016 Jan; 17(1):67-77. PubMed ID: 26652797
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
